Get Ready App helps monitor obesity patients before and after bariatric surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests a cloud-based digital monitoring solution for patients eligible for bariatric surgery. Get Ready, built on the Maela platform, guides care pathways, collects questionnaires and reminders, and alerts clinicians to patient needs. The aim is to streamline care, reduce in-person visits, and lower rates of procedure cancellations due to communication issues. The study will assess how the app supports healthcare teams and patients throughout the surgical journey. It is conducted at a single center in Rome with industry collaboration from Medtronic.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients affected by morbid obesity and eligible for bariatric surgery according to SICOB guidelines (aged between 18 and 65 years, inclusive; body mass index \> 35 kg/m² with obesity-related comorbidities or BMI \> 40 kg/m²)

Exclusion Criteria:

* Inability or difficulty in using smartphone or PC applications

Where it's running

• Fondazione Policlinico Universitario Campus Bio Medico di Roma
  Rome, Rm, Italy Recruiting

Study contacts

• Principal investigator: Vincenzo Bruni, General Surgeon, MD — Fondazione Policlinico Campus Bio-Medico di Roma
• Study coordinator: Chiara Isabella Miligi, General Surgeon, MD
• Email: c.miligi@policlinicocampus.it
• Phone: +393891015712

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.